1
|
Zanardi E, Grassi P, Cavo A, Verzoni E, Maggi C, De Braud F, Boccardo F, Procopio G. Treatment of elderly patients with metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2016; 16:323-34. [PMID: 26654225 DOI: 10.1586/14737140.2016.1131613] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The risk of developing renal cell carcinoma (RCC) increases with age, and given the constant gain in life expectancy of the general population, both localized RCC and metastatic RCC (mRCC) are more frequently observed in the elderly population. The elderly are a heterogeneous group of patients often characterized by the presence of comorbidities, different compliance to treatment and polypharmacy. Here we review the available data with the aim to analyze the safety and efficacy of new targeted therapies (TTs) in elderly mRCC patients. TTs seem to be effective in both older and younger patients, but elderly patients appear to show reduced tolerance to treatments compared to younger patients. Prospective trials are needed to better understand how to manage mRCC in elderly patients.
Collapse
Affiliation(s)
- Elisa Zanardi
- a Academic Unit of Medical Oncology , IRCCS San Martino University Hospital-IST National Cancer Research Institute , Genoa , Italy.,b Department of Medicine , School of Medicine, University of Genoa , Genoa , Italy
| | - Paolo Grassi
- c Department of Medical Oncology 1 , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy
| | - Alessia Cavo
- a Academic Unit of Medical Oncology , IRCCS San Martino University Hospital-IST National Cancer Research Institute , Genoa , Italy.,b Department of Medicine , School of Medicine, University of Genoa , Genoa , Italy
| | - Elena Verzoni
- c Department of Medical Oncology 1 , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy
| | - Claudia Maggi
- c Department of Medical Oncology 1 , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy
| | - Filippo De Braud
- c Department of Medical Oncology 1 , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy
| | - Francesco Boccardo
- a Academic Unit of Medical Oncology , IRCCS San Martino University Hospital-IST National Cancer Research Institute , Genoa , Italy.,b Department of Medicine , School of Medicine, University of Genoa , Genoa , Italy
| | - Giuseppe Procopio
- c Department of Medical Oncology 1 , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy
| |
Collapse
|
2
|
Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MMEM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eur Urol 2015; 68:837-47. [PMID: 25952317 DOI: 10.1016/j.eururo.2015.04.017] [Citation(s) in RCA: 104] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Accepted: 04/13/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Understanding how to sequence targeted therapies for metastatic renal cell carcinoma (mRCC) is important for maximisation of clinical benefit. OBJECTIVES To prospectively evaluate sequential use of the multikinase inhibitors sorafenib followed by sunitinib (So-Su) versus sunitinib followed by sorafenib (Su-So) in patients with mRCC. DESIGN, SETTING, AND PARTICIPANTS The multicentre, randomised, open-label, phase 3 SWITCH study assessed So-Su versus Su-So in patients with mRCC without prior systemic therapy, and stratified by Memorial Sloan Kettering Cancer Center risk score (favourable or intermediate). INTERVENTION Patients were randomised to sorafenib 400mg twice daily followed, on progression or intolerable toxicity, by sunitinib 50mg once daily (4 wk on, 2 wk off) (So-Su), or vice versa (Su-So). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoint was improvement in progression-free survival (PFS) with So-Su versus Su-So, assessed from randomisation to progression or death during second-line therapy. Secondary endpoints included overall survival (OS) and safety. RESULTS AND LIMITATIONS In total, 365 patients were randomised (So-Su, n=182; Su-So, n=183). There was no significant difference in total PFS between So-Su and Su-So (median 12.5 vs 14.9 mo; hazard ratio [HR] 1.01; 90% confidence interval [CI] 0.81-1.27; p=0.5 for superiority). OS was similar for So-Su and Su-So (median 31.5 and 30.2 mo; HR 1.00, 90% CI 0.77-1.30; p=0.5 for superiority). More So-Su patients than Su-So patients reached protocol-defined second-line therapy (57% vs 42%). Overall, adverse event rates were generally similar between the treatment arms. The most frequent any-grade treatment-emergent first-line adverse events were diarrhoea (54%) and hand-foot skin reaction (39%) for sorafenib; and diarrhoea (40%) and fatigue (40%) for sunitinib. CONCLUSIONS Total PFS was not superior with So-Su versus Su-So. These results demonstrate that sorafenib followed by sunitinib and vice versa provide similar clinical benefit in mRCC. PATIENT SUMMARY We investigated if total progression-free survival (PFS) is improved in patients with advanced/metastatic kidney cancer who are treated with sorafenib and then with sunitinib (So-Su), compared with sunitinib and then sorafenib (Su-So). We found that total PFS was not improved with So-Su compared with Su-So, but both treatment options were similarly effective in patients with advanced/metastatic kidney cancer. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT00732914, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- Christian Eichelberg
- Universitätsklinikum Hamburg-Eppendorf, Hamburg and Caritas-St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
| | | | - Maria De Santis
- Ludwig Boltzmann Institute for Applied Cancer Research, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria
| | | | - Peter J Goebell
- Urologische Klinik und Klinik für Hämatologie und Onkologie, Universitätsklinikum Erlangen, Erlangen, Germany
| | | | - Uwe Zimmermann
- Urologische Universitätsklinik Greifswald, Greifswald, Germany
| | | | | | | | | | | | - Maartje Los
- St. Antonius Ziekenhuis, Nieuwegein, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol 2014; 10:1741-50. [DOI: 10.2217/fon.14.48] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
ABSTRACT Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first- or second-line single-agent sorafenib between January 2008 and December 2010 were eligible. Retrospective data collection started in 2012 and covers at least 1-year follow-up. The primary end point was overall survival (OS). Results: Median OS was 17.2 months (95% CI: 15.5–19.6): 19.9 months (95% CI: 15.9–25.3) in patients treated with first-line sorafenib and 16.3 months (95% CI: 13.1–18.2) with second-line sorafenib. Overall median (95% CI) progression-free survival was 5.9 months (95% CI: 4.9–6.7): 6.6 (95% CI: 4.9–9.3) and 5.3 months (95% CI: 4.3–6.0) in first- and second-line patients, respectively. Conclusion: The efficacy and safety of sorafenib in routine community practice was generally good, especially in relation to OS in patients treated in the second line, where results were similar to those seen in recent prospective clinical trials.
Collapse
Affiliation(s)
- Giuseppe Procopio
- S.C. Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133 Milano, Italy
| | - Lisa Derosa
- U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Via Roma 67, 56100 Pisa, Italy
| | - Angela Gernone
- U.O. Oncologia Medica Universitaria, Azienda Ospedaliera Policlinico di Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Franco Morelli
- U.O.C. Oncologia, Casa Sollievo della Sofferenza, Viale Cappucini 1, 71013 San Giovanni Rotondo (FG), Italy
| | - Teodoro Sava
- Oncologia Medica d.O., Azienda Ospedaliera Universitaria Integrata Verona, Borgo Trento, P.le Stefani 1, 37126 Verona, Italy
| | - Fable Zustovich
- Oncologia Medica 1, Istituto Oncologico Veneto – IRCCS, Via Gattamelata 64, 35127 Padova, Italy
| | - Ugo De Giorgi
- IRCCS Istituto Scientifico Romagnolo, per lo Studio e la Cura dei Tumori (I.R.S.T.), Via Piero Maroncelli 40, 47014 Meldola (FC), Italy
| | - Vittorio Ferrari
- U.O. Oncologia Medica, Spedali Civili Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
| | - Roberto Sabbatini
- Medical Oncology Division, Azienda Ospedaliero Universitaria, Policlinico di Modena, 41125 Modena, Italy
| | - Donatello Gasparro
- Azienda Ospedaliero-Universitaria di Parma, Dipartimento Onco-Ematogico, Oncologia Medica, Via Gramsci 14, 40126 Parma, Italy
| | - Alessandra Felici
- Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Luciano Burattini
- Oncologia Clinica, Ospedali Riuniti, Via Conca 71, 60100 Ancona, Italy
| | - Nicola Calvani
- Medical Oncology Division & Breast Unit, Sen. Antonio Perrino Hospital, S.S. 7, 72100 Brindisi, Italy
| | - Giovanni Lo Re
- Divisine di Oncologia, Azienda Ospedaliera Santa Maria degli Angeli, Via Montereale 24, 33170 Pordenone, Italy
| | - Giuseppe Banna
- Division of Medical Oncology, Cannizzaro Hospital, Via Messina 829, 95126, Catania, Italy
| | - Maria Pia Brizzi
- Department of Oncology, Medical Oncology, A.O.U. San Luigi, Regione Gonzole 10, 10043, Orbassano (TO), Italy
| | - Mimma Rizzo
- A.O.R.N. “A. Cardarelli”, U.O.S.C. Oncologia, Via A. Cardarelli 9, 80131 Napoli, Italy
| | - Libero Ciuffreda
- Direttore S.C. Oncologia Medica 1, Dipartimento Oncologia ed Ematologia, A.O.Citta’ della Salute e della Scienza – Ospedale Molinette, C.so Bramante 88, 10126 Torino, Italy
| | - Roberto Iacovelli
- Oncology Unit B, Department of Radiology, Oncology & Human-Pathology, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
| | - Francesco Ferraù
- Medical Oncology Unit, “S.Vincenzo” Hospital, C.da Sirina, 98039 Taormina, Italy
| | - Eleonora Taibi
- Humanitas Centro Catanese di Oncologia S.p.A, Via V. E. Da Bormida 64, 95126 Catania (CT), Italy
| | - Sergio Bracarda
- Dipartimento Oncologico UOC, Ospedale S. Donato USL 8Toscana, Via Pietro Nenni 20, 52100 Arezzo, Italy
| | - Camillo Porta
- Medical Oncology, IRCCS San Matteo, University Hospital Foundation, Viale Camillo Golgi 19, 27100 Pavia, Italy
| | - Enzo Galligioni
- Dipartimento di Oncologia, Azienda Provinciale per i Servizi Sanitari, Trento, Ospedale S.Chiara, 38122 Trento, Italy
| | - Antonio Contu
- SC di Oncologia Medica, ASL n°1, Via De Nicola 14, 07100 Sassari, Italy
| |
Collapse
|
5
|
Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 2013; 108:311-8. [PMID: 23322192 PMCID: PMC3566810 DOI: 10.1038/bjc.2012.543] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2012] [Revised: 11/08/2012] [Accepted: 11/10/2012] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (<55, 55-<65, 65-<75, or ≥ 75 years). METHODS Dosing patterns, and incidence, prevalence and cumulative incidence of drug-related adverse events (DRAEs) and fatal DRAEs were assessed. RESULTS Overall, 4684 patients were evaluable (<55 years, n=1126; 55-<65, n=1579; 65-<75, n=1382; ≥ 75, n=559). Treatment patterns were generally similar across subgroups, although sorafenib treatment duration was ∼30% shorter in the ≥ 75-years subgroup. There were no substantial differences in any-grade DRAEs with sorafenib between subgroups. Drug-related adverse events and dose modifications due to DRAEs tended to occur in months 0-3 and declined thereafter; there was no evidence of cumulative toxicity. Fatal DRAEs were rare (0.7% overall; 95% confidence interval, 0.5-1.0%). CONCLUSION Sorafenib was well tolerated regardless of age in a heterogeneous population of RCC patients.
Collapse
Affiliation(s)
- G Procopio
- Department of Medical Oncology 1, Fondazione IRCCS 'Istituto Nazionale Tumori', Milan, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|